# US 2021/0330817 A1 · Synthetic dna vectors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330817 A1
- Document ID: US20210330817A1
- Status: Published application
- Kind: A1
- Application number: 17/365,805
- Filed: 2021-07-01
- Published: 2021-10-28
- Earliest claimed: 2019-09-18
- Assignees: Intergalactic Therapeutics, Inc.
- Applicants: Intergalactic Therapeutics, Inc.
- Inventors: Bruce C. Schnepp; Philip R. Johnson
- Web page: https://patentgrep.com/patent/US20210330817A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 15/86: Viral vectors
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene.

## Claims

### Claim 1

A method of expressing a polypeptide in a subject, the method comprising:
(a) administering to the subject a synthetic circular DNA vector comprising a gene encoding the polypeptide, wherein the synthetic circular DNA vector lacks an origin of replication, a drug resistance gene, and a site-specific recombination recognition site; and
(b) expressing the polypeptide in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein expression of the polypeptide persists in a target tissue in the subject for at least two weeks after the administering.

### Claim 3 (depends on 2)

The method of claim 2, wherein expression of the polypeptide persists in the target tissue for at least two months after the administering.

### Claim 4 (depends on 3)

The method of claim 3, wherein the target tissue is liver tissue, breast tissue, kidney tissue, prostate tissue, esophageal tissue, gastric tissue, stomach tissue, colorectal tissue, bladder tissue, retinal tissue, brain tissue, lung tissue, tumor tissue, or cutaneous tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein the synthetic circular DNA vector is comprised in a pharmaceutical composition.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is substantially devoid of one or more of the following: endotoxins, bacterial contaminants, flagellin, lipoteichoic acid, and peptidoglycan.

### Claim 7 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition further comprises a delivery vehicle selected from liposomes, nanoparticles, microparticles, microspheres, lipid particles, vesicles, polyaxamer, and polycationic material.

### Claim 8 (depends on 1)

The method of claim 1, wherein the synthetic circular DNA vector further comprises a promoter sequence upstream of the gene, wherein the promoter sequence is substantially devoid of CpG islands.

### Claim 9 (depends on 8)

The method of claim 8, wherein the synthetic circular DNA vector further comprises a polyadenylation site downstream of the gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein the synthetic circular DNA vector is supercoiled.

### Claim 11 (depends on 10)

The method of claim 10, wherein the synthetic circular DNA vector is monomeric supercoiled.

### Claim 12 (depends on 1)

The method of claim 1, wherein the administering is performed intravenously, intramuscularly, intravitreally, intraocularly, intraorbitally, subretinally, intradermally, intracerebrally, intrathecally, intratumorally, intratracheally, intrapleurally, by eye drop, or by inhalation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the gene is at least 5 Kb in length.

### Claim 14 (depends on 1)

The method of claim 1, wherein the synthetic circular DNA vector is substantially devoid of CpG islands.

### Claim 15 (depends on 1)

The method of claim 1, wherein the administering is performed at least a first time and a second time.

### Claim 16 (depends on 15)

The method of claim 15, wherein the second time is at least 2 weeks after the first time.

### Claim 17 (depends on 16)

The method of claim 16, wherein the administering is additionally performed at least a third time, wherein the third time is at least 2 weeks after the second time.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administering elicits a reduced immune response compared to a control vector.

### Claim 19 (depends on 18)

The method of claim 18, wherein the control vector is a vector produced in a bacterial cell.

### Claim 20 (depends on 1)

The method of claim 1, wherein administering the synthetic circular DNA vector does not cause significant increases of cytokine levels in the subject.

### Claim 21 (depends on 1)

The method of claim 1, wherein the gene is expressible in a target cell selected from a liver cell, an ocular cell, a stem cell, a neural cell, a muscle cell, or a blood cell.
